Clinical Trial Update: Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial assessing the safety and efficacy of low-dose MM120 for attention-deficit/hyperactivity disorder has completed, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• MM120

Snippet

Sponsor: Definium Therapeutics US, Inc. | Conditions: ADHD, Attention Deficit Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-04-13